Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
評估使用固定比例的 insulin degludec 和 liraglutide 進行代謝介入的 2 型糖尿病緩解情況:一項隨機對照試驗。
Diabetes Obes Metab 2024-09-06
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
直接比較固定比例組合的胰高血糖素受體激動劑和基礎胰島素對第2型糖尿病的血糖和非血糖參數的影響。
BMC Endocr Disord 2023-02-06
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
糖尿病在進行強化代謝干預(結合胰島素格拉凝/lixisenatide、二甲双胍和生活方式方法)後的緩解和復發:隨機對照試驗結果。
Diabetes Obes Metab 2023-10-04
Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience.
使用 IDegLira 來加強、簡化和提高第二型糖尿病治療的適當性:一個真實生活經驗。
Diabetes Ther 2024-04-26
Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
糖尿病2型患者中葡萄糖降低藥物對β細胞反應和胰島素敏感度的長期影響:GRADE隨機臨床試驗。
Diabetes Care 2024-04-04
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
糖尿病2型患者使用胰高血糖素樣肽-1受體激動劑後的治療強化:GLP-1 RA與基礎胰島素自由組合對比固定組合的比較效果分析。RESTORE-G 實務研究。
Nutr Metab Cardiovasc Dis 2024-05-01
De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test.
從基礎玻璃胰素治療轉換至利拉魯肽在2型糖尿病中的減弱:禁食測試期間平均血糖的預測價值。
Life (Basel) 2024-05-25
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
Liraglutide 增強胰島素分泌並延長新診斷 1 型糖尿病成人的緩解期(NewLira 研究):一項隨機、雙盲、安慰劑對照試驗。
Diabetes Obes Metab 2024-08-28
Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients.
早期將強化胰島素療法轉換為IDegLira在降低2型糖尿病患者的空腹血糖和HbA1c方面顯示出更高的療效和安全性。
Diabetes Metab Syndr Obes 2024-09-03